In addition, the levels of miRNAs from peripheral blood can accurately predict p-Tau/Aβ42 ratio in CSF, indicating potential for a non-invasive protocol for early screening and diagnosis of AD (Campbell et al., 2021; Jia et al., 2021; Wang J. et al., 2018). The gene discussed is MAPT; the disease is Alzheimer disease.